Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D. Campbell, Esther Drill, Christina Yau et al.|Cell Reports|2018Cited by 366
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, R. Eric Davis et al.|The Lancet Oncology|2014Cited by 263
Analysis of Cell Mechanics in Single Vinculin-Deficient Cells Using a Magnetic TweezerFrancis J. Alenghat, Donald E. Ingber, Ben Fabry et al.|Biochemical and Biophysical Research Communications|2000Cited by 214
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Jingjing Jiang et al.|Nature|2024Cited by 175
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediatesVida Chitsazzadeh, Kenneth Y. Tsai, Cristian Coarfa et al.|Nature Communications|2016Cited by 159